Arecor Therapeutics plc announced that it has signed a further collaboration agreement with Eli Lilly and Company. Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestattm, to develop a novel liquid formulation of one of Lilly's products with enhanced properties. Lilly will fund the development work and has the option to acquire the rights to the new formulation and newly created intellectual property under a technology licensing model to further develop and commercialise the product.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136.5 GBX | 0.00% | +6.23% | -25.21% |
Apr. 23 | Arecor chief financial officer to leave in July after five years | AN |
Apr. 23 | Arecor Therapeutics CFO to Leave in July | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.21% | 52.07M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AREC Stock
- News Arecor Therapeutics plc
- Arecor Therapeutics plc Signs Further Collaboration Agreement with Lilly and Company